Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD(+) synthesis via enterohepatic circulation

Yaku K, Palikhe S, Iqbal T, Hayat F, Watanabe Y, Fujisaka S, et al. | Sci Adv | 2025 | Evidence: limited

Plain-language summary

Published 2025 in Sci Adv, this work by Yaku K and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

Mechanistic study in Sci Adv (2025) on NAD+/sirtuin/longevity biology
Adds to the foundational literature underlying NMN supplementation rationale
First author: Yaku K

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to science decisions, with secondary relevance to compare. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

Where we cite this paper

← Back to research index